New scSNV-seq technique unveils genetic drivers of diseases like cancer and Alzheimer’s

FHS
March 4, 2024
9:31 am

Scientists have developed a new screening tool to uncover how genetic changes affect gene activity and can lead to diseases such as cancer, autoimmunity, neurodegeneration and cardiovascular disease. This new tool enables the investigation of thousands of DNA mutations identified by genetic studies in one experiment, guiding the development of advanced diagnostics and treatments.

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity 18-Apr-2024 / 07:02 CET/CEST Biophytis

April 19, 2024

Algernon Pharmaceuticals Announces Private Placement | Psychedelic Invest

British Columbia – Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the ‘Company’ or ‘Algernon’) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement

July 12, 2024

Rhode Island Advances Psilocybin Reform With Bill To Legalize Therapeutic Access And Cultivation

Rhode Island is making progress in the area of psychedelics reform as lawmakers approved a bill that could legalize psilocybin mushrooms. The legislation, introduced by Rep. Brandon Potter (D) received

June 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.